A monthly prescription of Wegovy or Zepbound runs $1,000–1,350 cash in 2026. Compounded semaglutide or tirzepatide runs $200–400/month from most telehealth providers. That price gap drove a massive shift toward compounded GLP-1 starting around 2022. The regulatory and safety picture behind the price is more nuanced than the marketing on either side.
How compounding GLP-1 became widespread
When Wegovy and Mounjaro launched in 2021–2022, demand outstripped supply. The FDA designated both as "in shortage," which under 503A and 503B regulations allows compounding pharmacies to produce versions of the drug to fill clinical need. Telehealth providers built large patient bases around compounded semaglutide and tirzepatide during this period.
The shortage status changed in 2024 — tirzepatide came off the shortage list in October 2024, semaglutide in early 2025. FDA guidance issued at the time gave compounders a wind-down window. As of mid-2026, the legal status of newly produced compounded GLP-1 is in flux, with ongoing legal challenges and state-by-state variation in enforcement. This is one of the most actively shifting regulatory landscapes in US healthcare; verify current status before starting.
What "compounded" means here
Compounded semaglutide and tirzepatide are produced by 503A pharmacies (under individual prescription) or 503B "outsourcing facilities" (production at scale under stricter FDA oversight). The active pharmaceutical ingredient (API) is sourced from API suppliers, dissolved in a sterile carrier (bacteriostatic water, sometimes vitamin B12 or other additives), and dispensed in multi-dose vials.
Key distinctions: 503A pharmacy compounded products are NOT FDA-approved drugs. 503B outsourcing-facility products are also not FDA-approved but operate under more inspection. Neither has gone through randomized trials specific to the compounded formulation; safety inference is by analogy to FDA-approved semaglutide/tirzepatide.
The dose accuracy issue
In 2024, an investigation by the Endocrine Society found significant dose variability across compounded GLP-1 samples — some over-dosed, some under-dosed, some contaminated with related but different molecules. Reputable 503B facilities with third-party potency testing produce more consistent product. Some 503A pharmacies do not publish potency testing.
The "salt form" issue
Some compounded products use semaglutide sodium or semaglutide acetate rather than the base semaglutide molecule. These salt forms have not been clinically tested. FDA has explicitly stated they are not equivalent to FDA-approved semaglutide. If you're considering compounded GLP-1, ask explicitly which form of the API is used.
Adverse event reporting
FDA-approved Wegovy and Zepbound have post-market adverse event surveillance through MedWatch and FAERS. Compounded products do not have the same centralized tracking. A patient experiencing a serious side effect from compounded semaglutide may face longer reporting paths and less aggregate visibility into emerging safety signals.
How to decide
If insurance covers Wegovy or Zepbound at a manageable copay, the regulatory and oversight picture favors branded. If insurance won't cover and cash branded is unaffordable, compounded becomes the practical option — in which case the questions to ask are: Is this 503A or 503B? What's the API form? Is potency testing published? What's the adverse event escalation path? How recent is the legal status under FDA guidance?
Informational only — discuss with a clinician who can assess your specific situation and the current regulatory state.